La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Skye Bioscience a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Skye Bioscience..

Skye Bioscience (NASDAQ:SKYE) Azioni, Catena delle Opzioni

Skye Bioscience

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Skye Bioscience Inc

Skye Bioscience Inc Ordinary Shares

Skye Petroleum Inc

News

Health Care

Press Releases

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions

General

Skye Bioscience Shares Nimacimab "Anatomy of Progress" Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

Earnings

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

Skye's CB1 Inhibitor, Nimacimab,  Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting

Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial

SKYE

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Alpha Cognition

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Agenus

Anika Therapeutics

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

C4 Therapeutics

Compugen

Climb Bio

Cardiff Oncology

Citius Oncology

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals

Fate Therapeutics

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

Genelux

TuHURA Biosciences

MDxHealth

Molecular Partners AG - American Depositary Shares

Molecular Partners

Nkarta

Nuvectis Pharma

Oncolytics Biotech

Ovid Therapeutics

Pyxis Oncology

AVITA Medical

Tevogen Bio Holdings

HC Wainwright & Co.

Evercore ISI Group

JMP Securities

Craig-Hallum

Citizens Capital Markets

WIIM

Skye Bioscience shares are trading lower after the company announced the nimacimab monotherapy arm did not meet primary endpoint in CBeyond study.

Comments

Skye Bioscience

Skye Bioscience (SKYE) Opzioni

Skye Bioscience (NASDAQ:SKYE) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO